Vimpat (Lacosamide) is a prescription antiepileptic medication used to control and reduce the frequency of seizures. It works by stabilizing hyperexcitable neuronal membranes in the brain, selectively enhancing the slow inactivation of sodium channels without affecting normal physiological function. This targeted approach helps manage abnormal electrical activity that leads to seizures.

Key Features

• Dual-Action Stabilization: Specifically targets voltage-gated sodium channels to inhibit repetitive neuronal firing.
• Flexible Monotherapy or Adjunctive Use: Can be used as a standalone treatment or in combination with other antiepileptic drugs.
• High Bioavailability: Quickly absorbed by the body with low protein binding, which minimizes the risk of interactions with other medications.
• Convenient Blister Pack: The 56-tablet pack is designed for a standard 28-day supply (based on twice-daily dosing).
• Consistent Efficacy: Clinically proven to reduce the frequency of partial-onset seizures in adults and children.

Primary Uses

• Partial-Onset Seizures: Used to treat seizures that begin in a specific area of the brain, with or without secondary generalization (spreading to other parts of the brain).
• Primary Generalized Tonic-Clonic Seizures: Approved as an adjunctive therapy for patients with idiopathic generalized epilepsy.
• Ongoing Epilepsy Management: Intended for long-term seizure control under strict medical supervision.